地舒单抗一支多少钱

Desosumab is also known as denosumab, denosumab, Xgeva, and Denosumab. It is a human monoclonal antibody and the first RANKL inhibitor approved by the FDA. Osteoclasts are cells that break down bone (bone resorption), and denosumab works by blocking the development of osteoclasts and is used to treat osteoporosis, treatment-induced bone loss, metastasis to the bone, and giant cell tumor of bone, and to reduce the risk of fractures in cancer patients. Desosumab was developed by biotechnology company Amgen. Denosumab is contraindicated in people with low blood calcium levels.

In patients with giant cell tumors of bone, osteoclast-like tumor-associated giant cells can be significantly reduced or even eliminated by inhibiting RANKL secreted by denosumab on tumor stromal components. Only reduced osteolysis can prevent further progression of giant cell tumors, when the proliferative matrix is ​​replaced by dense non-proliferative, differentiated woven new bone, thereby effectively improving clinical outcomes. Desosumab may serve as a targeted therapy for giant cell tumor of bone and may become an important treatment option to fill an unmet medical need in this disease. The State Food and Drug Administration conditionally approved the marketing of this product on May 21, 2019. At the same time, the applicant is required to continue clinical research in my country and formulate and strictly implement a risk management plan after the product is approved.

The United States is the place where the most new drugs are launched in the world. Outside the United States, Europe, Germany/France/Russia/Turkey, and Asia Japan/India/Bangladesh/Taiwan/Hong Kong/Mainland China are all countries that develop, manufacture and market the latest specific drugs and generic drugs. The actual price of the same drug in various regions is affected by customs tariffs, logistics costs, drug consistency testing fees, drug regulatory filing license fees, pharmacy distribution channel fees, international foreign exchange price changes, API and finished drug manufacturing cycles, medical insurance, and compliance costs limited by local laws and regulations in your community. There are great differences. Currently, denosumab in China is ¥5298.00 unit/RMB.